Bridging knowledge and practice in dermatology: Implementing JAK inhibitors in real-world alopecia areata
In recent years, Janus kinase (JAK) inhibitors have transformed the treatment landscape for alopecia areata (AA), however challenges remain in assessing disease severity and confidently incorporating these therapies into routine practice. This educational program provides practical, case-based guidance to help clinicians evaluate AA severity beyond percentage scalp hair loss, understand JAK inhibitor safety and efficacy, and integrate these treatments into personalized patient care.
Complete both case studies and be awarded up to 0.5 AMA PRA Category 1 Credit(s)™.To claim your certificate, complete all educational content and the evaluation forms at the end of each activity.
Start this program
Learning activities
Amy McMichael
Arash Mostaghimi
- Evaluate severity of AA by combining objective measures and real-world clinical considerations.
- Apply knowledge of JAK inhibitor safety data to make informed treatment decisions and manage treatment-related side effects.
- Integrate JAK inhibitors into comprehensive AA treatment strategies, incorporating real-world evidence and patient-specific factors.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Health+ IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 30th September 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Springer Health+ IMEplanners and others have nothing to disclose.
All relevant financial relationships have been mitigated.
This independent medical education program is designed for US-based dermatologists and advanced practice providers (APPs) who treat patients with alopecia areata.
